Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

OGN earnings analysis

Filed May 4, 2026 · Our reading of the company's report

The latest report

Organon reported declining financial performance for Q1 2026, with revenue of $1.460 billion and diluted EPS of $0.71, both missing analyst expectations. Notably, segments saw declines in Women’s Health and Established…

Read full summary

Organon reported declining financial performance for Q1 2026, with revenue of $1.460 billion and diluted EPS of $0.71, both missing analyst expectations. Notably, segments saw declines in Women’s Health and Established Brands, though some growth was recorded in Biosimilars. The ongoing merger with Sun Pharma complicates forward guidance as management shifts focus.

Read the original on SEC.gov

Reported figures

Earnings per share
$0.71
Segment
Women's Health: $360 million, General Medicines: $1.100 billion

What stood out

  • Revenue Missed Expectations

    Actual revenue of $1.460 billion fell short of the estimated $1.484 billion.

  • EPS Missed Consensus

    Diluted EPS came in at $0.71, below the anticipated $0.84, reflecting a miss of 15.5%.

  • Notable Segment Performance

    Revenue in Women's Health declined 19%, particularly impacted by Nexplanon sales dropping from $248 million to $201 million.

  • Positive Cash Flow Generation

    Net cash provided by operating activities was $225 million for Q1 2026, up from $75 million in Q1 2025.

  • Cash Reserves Increase

    Cash and cash equivalents rose to $1.12 billion as of March 31, 2026.

  • Restructuring Cost Reduction

    Restructuring costs decreased significantly to $31 million from $86 million year-over-year.

What to watch

  • Pending Merger Risk

    The merger with Sun Pharma may not close as expected due to various regulatory and approval conditions.

  • Material Weakness in Controls

    Continuing material weaknesses in internal control over financial reporting could impact reliability in financial disclosures.

  • Sales Decline Across Key Products

    Nexplanon and other key products have seen significant declines in demand, signaling potential long-term challenges.

Management's outlook

No forward guidance provided due to ongoing merger with Sun Pharma.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.